Skip to main content
GutCited

Saccharomyces boulardii para Antibiotic-Associated Diarrhea (AAD)

A

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Conclusão

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Efeito: L. rhamnosus GG used by 91.8% None

População: Italian primary care pediatricians

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Efeito: None None

População: Pediatric population

Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None vs: None Outcome: None Efeito: None None

População: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Efeito: None None

População: Pediatric patients with GI disorders

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None vs: None Outcome: C. difficile infection treatment outcomes Efeito: None None

População: Patients with C. difficile infection

Randomized Controlled Trial n=47 1 weeks
[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …
Dose: None vs: Control Outcome: Gut microbiota composition Efeito: None P<0.017

População: Children

Key Statistics

25

Estudos

5000

Participantes

Positive

A

Nota

Referenced Papers

Advances in experimental … 2024 2 citações
Archivos argentinos de … 2022 23 citações
Advances in experimental … 2019 17 citações
The American journal … 2018 46 citações
Journal of pediatric … 2016 233 citações
Digestive diseases (Basel, … 2016 37 citações
The Cochrane database … 2015 233 citações
Journal of clinical … 2015 35 citações
Expert opinion on … 2014 57 citações
Journal of clinical … 2011 432 citações
Journal for specialists … 2010 22 citações
American journal of … 2010
European journal of … 2009 91 citações
Current opinion in … 2009 82 citações
Advances in biochemical … 2008 535 citações
American family physician 2008
The Journal of … 2007 265 citações
The American journal … 2001 648 citações
International journal of … 2000 181 citações
Clinical infectious diseases … 1998 346 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Limite superior: Well-tolerated up to 1,000 mg/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Mixed 279
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Positive --
None 1 weeks Positive 47
None 20 weeks Positive 564
None -- Positive --

Melhor horário: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Efeitos Colaterais Relatados

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

Interações Conhecidas

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Ingestão máxima tolerável: Well-tolerated up to 1,000 mg/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Related Evidence

Outros ingredientes para Antibiotic-Associated Diarrhea (AAD)

Saccharomyces boulardii para outras condições

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.